Zydus, a discovery based global pharmaceutical company, announced that it has entered into a licensing agreement with China Medical System Holdings Limited for the development and commercialization of Desidustat, a novel oral HlF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not—on—dialysis and for the treatment of Anemia CKD patients […]
about people, work, and workplaces